Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ARVN logo ARVN
Upturn stock rating
ARVN logo

Arvinas Inc (ARVN)

Upturn stock rating
$9.52
Last Close (24-hour delay)
Profit since last BUY21.58%
upturn advisory
Consider higher Upturn Star rating
BUY since 31 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/17/2025: ARVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

21 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $18

1 Year Target Price $18

Analysts Price Target For last 52 week
$18 Target price
52w Low $5.9
Current$9.52
52w High $29.61

Analysis of Past Performance

Type Stock
Historic Profit -9.79%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 10/17/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 698.94M USD
Price to earnings Ratio -
1Y Target Price 18
Price to earnings Ratio -
1Y Target Price 18
Volume (30-day avg) 21
Beta 2.4
52 Weeks Range 5.90 - 29.61
Updated Date 10/18/2025
52 Weeks Range 5.90 - 29.61
Updated Date 10/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.01

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -19.47%
Operating Margin (TTM) -314.73%

Management Effectiveness

Return on Assets (TTM) -6.71%
Return on Equity (TTM) -12.01%

Valuation

Trailing PE -
Forward PE 17.7
Enterprise Value -170718895
Price to Sales(TTM) 1.87
Enterprise Value -170718895
Price to Sales(TTM) 1.87
Enterprise Value to Revenue 5.69
Enterprise Value to EBITDA -1.62
Shares Outstanding 73417595
Shares Floating 68475857
Shares Outstanding 73417595
Shares Floating 68475857
Percent Insiders 6.89
Percent Institutions 90.67

ai summary icon Upturn AI SWOT

Arvinas Inc

stock logo

Company Overview

overview logo History and Background

Arvinas Inc. was founded in 2013 based on the work of Dr. Craig Crews at Yale University. It pioneered PROTAC (proteolysis-targeting chimera) technology for targeted protein degradation. The company has focused on developing novel therapeutics for oncology and other diseases.

business area logo Core Business Areas

  • Oncology: Focused on developing PROTAC-based therapies for various cancers, including prostate cancer and breast cancer.
  • Neuroscience: Exploring the application of PROTAC technology to address neurological disorders.

leadership logo Leadership and Structure

Arvinas is led by John Houston, Ph.D., as President and CEO. The company has a board of directors and operates with a functional organizational structure, including research, development, clinical, and commercial teams.

Top Products and Market Share

overview logo Key Offerings

  • Bavdegalutamide (ARV-110): An investigational PROTAC degrader targeting the androgen receptor (AR) in metastatic castration-resistant prostate cancer (mCRPC). It's in Phase 3 clinical trials. Competitors include androgen receptor inhibitors like enzalutamide (Xtandi, manufactured by Astellas and Pfizer) and abiraterone acetate (Zytiga, manufactured by Johnson & Johnson). Market share data not yet available as product is not approved.
  • ARV-471: An investigational PROTAC estrogen receptor (ER) degrader being developed for the treatment of ER-positive/HER2-negative breast cancer. It is in Phase 3 clinical trials. Competitors include selective estrogen receptor degraders (SERDs) like fulvestrant (Faslodex, AstraZeneca) and selective estrogen receptor modulators (SERMs) like tamoxifen. Market share data not yet available as product is not approved.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly the oncology and neurodegenerative disease segments, is characterized by high growth potential, intense competition, and stringent regulatory requirements. Targeted protein degradation is an emerging field with potential to address previously undruggable targets.

Positioning

Arvinas is a leader in the PROTAC-based targeted protein degradation field. Its competitive advantage lies in its first-mover status and extensive intellectual property portfolio in this technology area.

Total Addressable Market (TAM)

The TAM for oncology and neurodegenerative disease therapies is very large, potentially exceeding hundreds of billions of dollars. Arvinas, with its novel PROTAC technology, is positioned to capture a significant share of this market if its therapies are successful in clinical trials and approved.

Upturn SWOT Analysis

Strengths

  • Pioneering PROTAC technology
  • Strong intellectual property portfolio
  • Experienced leadership team
  • Advancing clinical pipeline

Weaknesses

  • Reliance on novel technology with inherent risks
  • High cash burn rate due to R&D expenses
  • Dependence on clinical trial success
  • Currently no commercial products

Opportunities

  • Expanding PROTAC technology to new therapeutic areas
  • Partnering with larger pharmaceutical companies
  • Gaining regulatory approval for lead candidates
  • Developing next-generation PROTACs

Threats

  • Clinical trial failures
  • Competition from other targeted protein degradation approaches
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • KYTH
  • MRTX
  • LLY

Competitive Landscape

Arvinas faces competition from established pharmaceutical companies developing traditional therapies and other companies exploring targeted protein degradation. Arvinas's advantage is its focus on PROTACs, but it must demonstrate the clinical superiority of its approach.

Growth Trajectory and Initiatives

Historical Growth: Arvinas has experienced growth in terms of its pipeline and partnerships.

Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing bavdegalutamide and ARV-471 into Phase 3 trials, expanding partnerships, and exploring new PROTAC targets.

Summary

Arvinas is a pioneering biopharmaceutical company specializing in PROTAC technology for targeted protein degradation. Its focus on novel therapies for cancer and other diseases positions it for significant growth if clinical trials are successful. The company is navigating a competitive landscape and relies heavily on R&D. It needs to manage cash flow and mitigate risks associated with novel technology. Recent advancement of Bavdegalutamide and ARV-471 to phase 3 trails is a promising sign.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Arvinas Inc. Website
  • SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov
  • Company press releases

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market data is based on current estimates and may be subject to change. Investment decisions should be based on thorough research and consultation with a financial advisor.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Arvinas Inc

Exchange NASDAQ
Headquaters New Haven, CT, United States
IPO Launch date 2018-09-27
Chairperson, CEO & President Dr. John G. Houston Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 430
Full time employees 430

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.